false
0001583107
0001583107
2025-08-25
2025-08-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
August 25, 2025
THERAVANCE
BIOPHARMA, INC.
(Exact Name of Registrant as Specified in its
Charter)
| Cayman Islands |
|
001-36033 |
|
98-1226628 |
| (State
or Other Jurisdiction of |
|
(Commission
File Number) |
|
(I.R.S.
Employer Identification |
| Incorporation) |
|
|
|
Number) |
c/o
Theravance Biopharma US, LLC
901
Gateway Boulevard
South
San Francisco, CA 94080
(650)
808-6000
(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Ordinary
Share $0.00001 Par Value |
|
TBPH |
|
NASDAQ
Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events
On August 25, 2025, Theravance Biopharma, Inc. (NASDAQ: TBPH)
announced that it completed enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic
orthostatic hypotension (nOH) due to multiple system atrophy (MSA).
A copy of the press release is furnished as Exhibit 99.1 to this
Current Report.
The information in this Current Report (including Exhibit 99.1)
is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1)
shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| |
99.1 |
Press Release dated August 25, 2025 |
| |
|
|
| |
104 |
Cover Page Interactive
Data File (cover page XBRL tags embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
THERAVANCE BIOPHARMA, INC. |
| |
|
|
| Date: August 25, 2025 |
By: |
/s/ Aziz Sawaf |
| |
|
Aziz Sawaf |
| |
|
Senior Vice President and Chief Financial Officer |
